These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18421452)

  • 21. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs.
    Chamorro JG; Castagnino JP; Musella RM; Nogueras M; Aranda FM; Frías A; Visca M; Aidar O; Perés S; de Larrañaga GF
    J Gastroenterol Hepatol; 2013 Feb; 28(2):323-8. PubMed ID: 23190413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis.
    Bose PD; Sarma MP; Medhi S; Das BC; Husain SA; Kar P
    J Gastroenterol Hepatol; 2011 Feb; 26(2):312-8. PubMed ID: 21261721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.
    Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Zegarra-Chapoñan R; Sanchez C; Yufra-Picardo VM; Tarazona-Santos E; Ugarte-Gil C; Guio H
    Mol Genet Genomic Med; 2022 Aug; 10(8):e1987. PubMed ID: 35751408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of N-acetyltransferase-2 genotypes and anti-tuberculosis induced liver injury; first case-controlled study from Iran.
    Khalili H; Fouladdel S; Sistanizad M; Hajiabdolbaghi M; Azizi E
    Curr Drug Saf; 2011 Feb; 6(1):17-22. PubMed ID: 21047300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.
    Higuchi N; Tahara N; Yanagihara K; Fukushima K; Suyama N; Inoue Y; Miyazaki Y; Kobayashi T; Yoshiura K; Niikawa N; Wen CY; Isomoto H; Shikuwa S; Omagari K; Mizuta Y; Kohno S; Tsukamoto K
    World J Gastroenterol; 2007 Dec; 13(45):6003-8. PubMed ID: 18023090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.
    Ohno M; Yamaguchi I; Yamamoto I; Fukuda T; Yokota S; Maekura R; Ito M; Yamamoto Y; Ogura T; Maeda K; Komuta K; Igarashi T; Azuma J
    Int J Tuberc Lung Dis; 2000 Mar; 4(3):256-61. PubMed ID: 10751073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.
    Costa GN; Magno LA; Santana CV; Konstantinovas C; Saito ST; Machado M; Di Pietro G; Bastos-Rodrigues L; Miranda DM; De Marco LA; Romano-Silva MA; Rios-Santos F
    Mol Diagn Ther; 2012 Aug; 16(4):241-50. PubMed ID: 22788240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.
    Guaoua S; Ratbi I; Laarabi FZ; Elalaoui SC; Jaouad IC; Barkat A; Sefiani A
    BMC Genet; 2014 Dec; 15():156. PubMed ID: 25544508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.
    Leiro-Fernandez V; Valverde D; Vázquez-Gallardo R; Botana-Rial M; Constenla L; Agúndez JA; Fernández-Villar A
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1403-8. PubMed ID: 22283902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. tagSNP rs1495741 as a useful molecular marker to predict antituberculosis drug-induced hepatotoxicity.
    Chamorro JG; Castagnino JP; Musella RM; Nogueras M; Frías A; Visca M; Aidar O; Costa L; de Larrañaga GF
    Pharmacogenet Genomics; 2016 Jul; 26(7):357-61. PubMed ID: 27104815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study.
    Pourmohamadi N; Pour Abdollah Toutkaboni M; Hayati Roodbari N; Tabarsi P; Baniasadi S
    Iran J Med Sci; 2023 Sep; 48(5):474-483. PubMed ID: 37786472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
    Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
    Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.
    Zabost A; Brzezińska S; Kozińska M; Błachnio M; Jagodziński J; Zwolska Z; Augustynowicz-Kopeć E
    Biomed Res Int; 2013; 2013():853602. PubMed ID: 24383060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
    Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
    Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
    Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.
    Salazar-González R; Gómez R; Romano-Moreno S; Medellín-Garibay S; Núñez-Ruíz A; Magaña-Aquino M; Milán-Segovia RC; Portales-Pérez DP
    Mol Biol Rep; 2014 Dec; 41(12):7833-43. PubMed ID: 25163630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NAT2 polymorphisms associated with the development of hepatotoxicity after first-line tuberculosis treatment in Mexican patients: From genotype to molecular structure characterization.
    Herrera-Rodulfo A; Carrillo-Tripp M; Laura Yeverino-Gutierrez M; Peñuelas-Urquides K; Adiene González-Escalante L; Bermúdez de León M; Silva-Ramirez B
    Clin Chim Acta; 2021 Aug; 519():153-162. PubMed ID: 33932406
    [TBL] [Abstract][Full Text] [Related]  

  • 38.  NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.
    Lv X; Tang S; Xia Y; Zhang Y; Wu S; Yang Z; Li X; Tu D; Chen Y; Deng P; Ma Y; Chen D; Chen R; Zhan S
    Ann Hepatol; 2012; 11(5):700-7. PubMed ID: 22947533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.
    Singh N; Dubey S; Chinnaraj S; Golani A; Maitra A
    Mol Diagn Ther; 2009; 13(1):49-58. PubMed ID: 19351215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
    Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
    Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.